Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06359275
Other study ID # iPULSAR-PC
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date April 1, 2024
Est. completion date October 1, 2027

Study information

Verified date April 2024
Source Fudan University
Contact Si Shi, PHD
Phone +86-021-64179375
Email shisi@fudanpci.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial is a phase II clinical trial of the safety and efficacy of PD-1 antibody (Toripalimab) in combination with paclitaxel (albumin-bound type) and gemcitabine and PULSAR radiotherapy in patients with locally advanced unresectable pancreatic cancer and patients with only local recurrence after pancreatic cancer surgery, to observe the safety and efficacy of PD-1 antibody (Toripalimab) in combination with paclitaxel (albumin-bound type) and gemcitabine and PULSAR in the treatment of patients with locally advanced unresectable pancreatic cancer.


Description:

This trial is a phase II clinical trial of the safety and efficacy of PD-1 antibody (Toripalimab) in combination with paclitaxel (albumin-bound type) and gemcitabine and PULSAR radiotherapy in patients with locally advanced unresectable pancreatic cancer and patients with only local recurrence after pancreatic cancer surgery, to observe the safety and efficacy of PD-1 antibody (Toripalimab) in combination with paclitaxel (albumin-bound type) and gemcitabine and PULSAR in the treatment of patients with locally advanced unresectable pancreatic cancer. Progression-free survival (PFS), objective response rate (ORR), overall survival (OS), surgical conversion rate, and quality of life were observed in subjects with locally advanced unresectable pancreatic cancer with precise histological or cytological diagnosis and patients with only local recurrence after surgery. This is a single-center study. A total of 46 subjects with locally advanced unresectable pancreatic cancer and 35 subjects with locally recurrent pancreatic cancer after surgery were planned to be enrolled. The estimated enrollment time is 18 months, with at least 18 months of follow-up for each subject. This trial will evaluate the safety data of all subjects who have received at least one dose of study treatment for analysis. The National Cancer Institute (NCI) Common Adverse Event Evaluation Criteria (CTCAE version 5.0) were used. The efficacy evaluation was done according to the clinical diagnosis and treatment routine-follow-up patients combined with follow-up records.


Recruitment information / eligibility

Status Recruiting
Enrollment 81
Est. completion date October 1, 2027
Est. primary completion date December 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria 1. Sign the informed consent form. The subject has received a full explanation and understanding of the purpose, content, predicted efficacy, pharmacological effects, and risks of this trial, and the subject has signed an informed consent form; 2. Target group 1. Locally advanced pancreatic adenocarcinoma confirmed by histopathology or cytology, or pancreatic cancer with only local recurrence but no distant metastasis after surgery (local recurrence includes tumor bed recurrence and regional lymph node metastasis, which needs to be confirmed by biopsy pathology or PET -CT shows high metabolic activity, more than 6 months after the completion of postoperative adjuvant treatment); 2. There is at least one measurable objective lesion according to RECIST1.1 standards; 3. ECOG score 0-1 points; 4. Expected survival time = 3 months; 5. Willing to comply with research procedures and able to undergo treatment (including surgery) and follow-up; 6. There are no contraindications for the use of PD-1, PD-L1, gemcitabine and paclitaxel for injection (albumin-bound); 7. There are no contraindications to radiotherapy; 3. Abnormal physical examination and laboratory test results 1. Hematological dysfunction is defined as i) absolute neutrophil (ANC) count =1.5×109/L; ii) platelet (PLT) count: =80×109/L; iii) hemoglobin (Hb) level = 90g/L. 2. Abnormal liver function is defined as: i) Total bilirubin (TBil) level: = 1.5 times the upper limit of normal (ULN); ii) Aspartate aminotransferase (AST) and alanine; aminotransferase (ALT) levels = 2.5 times the ULN, if liver metastasis is present, =5 times ULN; 3. Abnormal renal function definition: serum creatinine = 1.5 times ULN, or calculated creatinine clearance = 50ml/min; 4. Definition of abnormal coagulation function: international normalized ratio (INR) = 1.5 times ULN, and prothrombin time (PT) or activated partial thromboplastin time (APTT) = 1.5 times ULN, unless the subject is receiving anti- Coagulation treatment. 4. Subjects who are positive for hepatitis B surface antigen (HBsAg) and whose peripheral blood hepatitis B virus deoxyribonucleic acid (HBV-DNA) titer is =1×103 copy number/L; if they are HBsAg-positive and whose peripheral blood HBV-DNA titer is detected =1×103 copy number/L, if the researcher believes that the subject's chronic hepatitis B is in a stable phase and will not increase the subject's risk, the subject is eligible for inclusion; 5. Age and reproductive status 1. Men and women aged 18-75; 2. Subjects of childbearing age must agree to take adequate contraceptive measures during the trial; the serum or urine pregnancy test of women of childbearing age must be negative 24 hours before the start of chemotherapy; 3. Women must be non-lactating. Exclusion criteria 1. Have received anti-PD-1 or anti-PD-L1 antibody treatment in the past; 2. Have received any investigational drugs within 4 weeks before using the investigational drugs for the first time; 3. Enroll in another clinical study at the same time, unless it is an observational (non-interventional) clinical study or an interventional clinical study follow-up; 4. Have received radiotherapy for the upper abdomen in the past; 5. Medical history and concurrent diseases 1. Uncontrolled serious medical diseases that the researcher believes will affect the subject's ability to receive the treatment of the research plan, such as combined with serious medical diseases, including severe heart disease, cerebrovascular disease, uncontrolled diabetes, and uncontrolled hypertension, uncontrolled infection, active peptic ulcer, etc; 2. Have active, known, or suspected autoimmune disease (including but not limited to uveitis, enteritis, hepatitis, hypophysitis, nephritis, vasculitis, hyperthyroidism, hypothyroidism, and need for bronchodilators treatment of asthma, etc.). Subjects with hypothyroidism requiring only hormone replacement therapy and skin diseases not requiring systemic treatment (such as vitiligo, psoriasis, or alopecia) were eligible; 3. Have active tuberculosis infection. Patients with active pulmonary tuberculosis infection within 1 year before the medication will be excluded, even if they have been treated; patients with a history of active pulmonary tuberculosis infection more than one year ago will also be excluded unless it is proven that they have previously received standard anti-tuberculosis treatment; 4. Previous interstitial lung disease or (non-infectious) pneumonia requiring oral or intravenous steroid therapy; 5. Long-term systemic corticosteroids (dose equivalent to >10 mg prednisone/day) or any other form of immunosuppressive treatment are required. Subjects using inhaled or topical corticosteroids were eligible; 6. Heart disease that is not well controlled, such as: 1. New York Heart Association (NYHA) grade 2 or above heart failure 2. Unstable angina pectoris 3. Myocardial infarction occurred within 1 year 4. Supraventricular or ventricular arrhythmias that are clinically significant and require treatment or intervention; 7. Dementia, altered mental status, or any mental illness that would prevent understanding or giving informed consent or completing questionnaires; 8. History of allergy or hypersensitivity reaction to any component of the treatment; 9. Malignant tumors within 5 years, except for fully treated basal cell or squamous cell carcinoma of the skin, localized prostate cancer after radical surgery, and breast ductal carcinoma in situ after radical surgery; 10. Previous systemic treatment for locally advanced pancreatic cancer; 11. Subjects who have been pathologically diagnosed with squamous cell carcinoma (not limited to organs) and received taxane-containing regimens as neoadjuvant/adjuvant treatment; 12. Subjects with = grade 2 peripheral neuropathy according to CTCAE version 5.0. 6. Hepatitis C virus (HCV) antibody positive or human immunodeficiency virus (HIV) antibody positive; 7. Active infection requiring systemic treatment; 8. Need to be combined with other anti-tumor drug treatments; 9. Have received any experimental drug treatment or participated in another interventional clinical trial within 30 days of the screening period; 10. The researcher believes that other circumstances are not suitable for inclusion.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
PD-1
Toripalimab,240 mg/time,D1, Q3W
Nab-paclitaxel
Nab-paclitaxel, 125mg/m2,IV,D1,8, Q3W
Gemcitabine
Gemcitabine,1000mg/m2,IV,D1,8,Q3W
Radiation:
PULSAR
5-10 Gy per session, a total of 5 times.

Locations

Country Name City State
China Fudan University Shanghai Cancer Center Shanhai

Sponsors (1)

Lead Sponsor Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free survival (PFS) PFS is defined as the time from randomization until the date of first occurrence of investigator-assessed radiological disease progression or death due to any cause, whichever came first. up to approximately 1 years
Secondary Progression-free survival (ORR) ORR is defined as the percentage of subjects with complete response (CR) or partial response (PR) by investigator assessment per RECIST criteria, version 1.1. up to approximately 1 years
Secondary Overall survival (OS) OS is defined as the time from the date of randomization to the date of death due to any cause. up to approximately 1 years
Secondary Surgical Conversion Rate The surgery is scheduled to take place after a minimum of 4 weeks from the last dose to allow the effects of the drug to wear off. The eligible subjects can undergo surgery within 8 weeks from the last dose. A successful resection is achieved when a patient achieves R0 or R1 resection. However, if a patient has R2 resection or unresectable, then it is considered as resection failure. The pathology committee of our center determines the surgical results of R0, R1, and R2 based on the tissue obtained during the operation. 18 weeks
See also
  Status Clinical Trial Phase
Completed NCT05305001 - Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Recruiting NCT06054984 - TCR-T Cells in the Treatment of Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT04927780 - Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer Phase 3
Recruiting NCT05919537 - Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Phase 1
Terminated NCT03140670 - Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy Phase 2
Terminated NCT00529113 - Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer Phase 1
Recruiting NCT05168527 - The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05391126 - GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care N/A
Terminated NCT03300921 - A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer Phase 1
Completed NCT03153410 - Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas Early Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Recruiting NCT05679583 - Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer Phase 2
Recruiting NCT04183478 - The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer Phase 2/Phase 3
Terminated NCT03600623 - Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Recruiting NCT05351983 - Patient-derived Organoids Drug Screen in Pancreatic Cancer N/A
Completed NCT04290364 - Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study